Roche boosts diagnostics business with 65 million-euro acquisition of PVT

17 March 2011

Swiss drug major Roche (SIX: ROG) aims to strengthen its position in laboratory automation clinical diagnostics with the acquisition of PVT Probenverteiltechnik GmbH based in Waiblingen, Germany and of PVT Lab Systems, in Atlanta, Georgia, USA. PVT is a global market leader in providing customized automation and workflow solutions for in-vitro diagnostic (IVD) testing in large commercial and hospital laboratories.

Under the terms of the deal, Roche will pay PVT shareholders an upfront payment of 65 million euros ($90 million), as well as up to 20 million euros on reaching performance-related milestones. The transaction is subject to customary closing conditions. PVT will become one of the competence centers inside Roche for the development and manufacturing of automation products.

Adds to current $11 billion diagnostics business

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK